Premium
Feasibility and outcomes of selective tetramodal bladder‐preservation therapy in elderly patients with muscle‐invasive bladder cancer
Author(s) -
Tanaka Hajime,
Fukushima Hiroshi,
Kijima Toshiki,
Nakamura Yuki,
Yajima Shugo,
Uehara Sho,
Yoshida Soichiro,
Yokoyama Minato,
Ishioka Junichiro,
Matsuoka Yoh,
Saito Kazutaka,
Fujii Yasuhisa
Publication year - 2020
Publication title -
international journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.172
H-Index - 67
eISSN - 1442-2042
pISSN - 0919-8172
DOI - 10.1111/iju.14179
Subject(s) - medicine , cystectomy , bladder cancer , sarcopenia , chemoradiotherapy , urology , cancer , surgery
Objective To assess the feasibility and functional/oncological outcomes of selective tetramodal bladder‐preservation therapy in elderly patients with muscle‐invasive bladder cancer. Methods This study analyzed 154 patients with non‐metastatic muscle‐invasive bladder cancer who were enrolled into the protocol. After maximal transurethral resection and induction chemoradiotherapy, patients with clinical complete response were offered consolidative partial cystectomy to achieve bladder preservation; otherwise, radical cystectomy was recommended. Postoperative complications, preserved bladder function, and oncological outcomes were compared between elderly (aged ≥75 years) and younger patients (aged <75 years). Frailty and sarcopenia were further assessed as potential factors that could affect the feasibility and outcomes of the protocol. Results A total of 44 patients (29%) were elderly, and 31 (20%) were frail (modified frailty index 2–3). Sarcopenia was observed in 68 (54%) of 126 eligible patients. Clinical complete response to induction chemoradiotherapy was achieved in 125 (81%) patients, and the bladder‐preservation protocol was completed in 107 (69%) patients with consolidative partial cystectomy. Over a median follow‐up period of 48 months, 5‐year cancer‐specific and muscle‐invasive bladder cancer recurrence‐free survival rates after protocol completion were 98% and 95%, respectively. There were no significant differences in complication rates related to partial cystectomy, preserved bladder function, and oncological outcomes between the elderly and younger groups. Neither frailty nor sarcopenia negatively affected these outcomes. Conclusions Tetramodal bladder‐sparing therapy incorporating consolidative partial cystectomy is feasible and yielded favorable functional/oncological outcomes in patients with muscle‐invasive bladder cancer, regardless of advanced age, frailty or sarcopenia. This protocol could be a viable treatment option for such high‐risk patient populations.